We can’t show the full text here under this license.
Abstract
Essence
Stopping GLP-1-based obesity therapies is commonly followed by weight regain and loss of cardiometabolic gains.
Evidence
This review summarizes real-world discontinuation data and randomized controlled trial evidence, including reports that up to 65% discontinue within a year and about two-thirds of lost weight is regained within a year after stopping.
Caveat
The abstract synthesizes existing evidence and proposes support frameworks rather than testing a specific post-discontinuation intervention.
Simplified
GLP-1 Therapies